LongeVC managing partner Sergey Jakimov joined Andreas Munk Holm on the EUVC podcast to discuss the firm's approach to longevity investing.
Sergey shared how LongeVC backs breakthroughs in biotech, AI-driven drug discovery, and the science of healthy aging, from early-stage spin-outs to major pharma partnerships. He also discussed the role of LongeVC's scientific advisory board in sourcing deals and why longevity and healthspan investing could be venture's next trillion-dollar frontier.
Listen to the full episode here.
Sergey shared how LongeVC backs breakthroughs in biotech, AI-driven drug discovery, and the science of healthy aging, from early-stage spin-outs to major pharma partnerships. He also discussed the role of LongeVC's scientific advisory board in sourcing deals and why longevity and healthspan investing could be venture's next trillion-dollar frontier.
Listen to the full episode here.